• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SNGX

    Soligenix Inc.

    Subscribe to $SNGX
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which has completed Phase I/II clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease and SGX201 for acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

    IPO Year:

    Exchange: NASDAQ

    Website: soligenix.com

    Recent Analyst Ratings for Soligenix Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Soligenix Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

      PRINCETON, N.J., May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025. "Our strategic focus remains on advancing our clinical programs, and we anticipate several significant development milestones. These include top-line results in 2026 from our actively enrolling Phase 3 confirmatory study of Hy

      5/9/25 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.

      AUSTIN, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializ

      5/7/25 8:00:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

      Interim Results from FDA-Funded Study Reinforces HyBryte's™ Rapid Response and Strong Safety Profile PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today interim results from the ongoing open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (CTCL). Following 18 weeks of treatment, 75% of patients achieved "Treatment Success," reinforcing HyBryte™ as

      4/14/25 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IBN Initiates Coverage of Soligenix Inc.

      AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with an unmet medical need, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts. Soligenix operates through two key segments: its Specialized BioTherapeutics division, which focuses on oncology and inflammation therapies, and its Public Health Solutions segment, which advances vaccines and therapeutics targeting biothreats and infectious diseases. The company is actively progressing

      3/25/25 8:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

      PRINCETON, N.J., March 21, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2024. "We remain highly focused on advancing our multiple clinical programs as we work towards achieving a number of important and potentially transformational development milestones, including top-line results in 2026 for our ac

      3/21/25 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

      Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J., March 6, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its lead investigators for the cutaneous T-cell lymphoma (CTCL) and psoriasis programs are presenting findings from recent supportive trials with HyBryte™ (synthetic hypericin) in the treatment of CTCL and SGX302 (synthetic hypericin) in the treatment of mild-to-moderate psoriasis. The

      3/6/25 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix to Present at BIO CEO & Investor Conference

      PRINCETON, N.J., Feb. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the BIO CEO & Investor Conference. The conference will be held February 10 - 11, 2025 in New York, N.Y. For more information about the BIO CEO & Investor Conference, please refer to the conference website at https://bcic.bio.org/. Registered conference a

      2/4/25 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix to Present at Upcoming Investor Conferences

      PRINCETON, N.J., Jan. 16, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming conferences below. Sequire Investor Summit, held January 21 to 23 at Condado Vanderbilt, Puerto Rico. For more information about the Sequire Investor Summit, please refer to the conference website at https://puertorico.srax.com/.The Microca

      1/16/25 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

      Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J., Jan. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL). The trial is sponsored by Ellen Kim, MD, Director, Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations, Dermatology Department, and P

      1/14/25 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

      FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). The confirmatory Phase 3 study (Fluorescent Light Activated Synthetic Hypericin 2, FLASH2), builds on the previous statistically significant Phase 3 (FLASH) study, as well as a recent successful comparative study (HPN-CTC

      12/16/24 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Soligenix Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Soligenix Inc.

      10-Q - SOLIGENIX, INC. (0000812796) (Filer)

      5/9/25 4:05:33 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Soligenix Inc.

      DEFA14A - SOLIGENIX, INC. (0000812796) (Filer)

      5/5/25 4:09:41 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Soligenix Inc.

      DEF 14A - SOLIGENIX, INC. (0000812796) (Filer)

      5/5/25 4:05:36 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - SOLIGENIX, INC. (0000812796) (Filer)

      3/28/25 4:05:36 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Soligenix Inc.

      EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

      3/27/25 12:15:12 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Soligenix Inc.

      EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

      3/27/25 12:15:10 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Soligenix Inc.

      EFFECT - SOLIGENIX, INC. (0000812796) (Filer)

      3/27/25 12:15:04 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Soligenix Inc.

      POS AM - SOLIGENIX, INC. (0000812796) (Filer)

      3/21/25 4:09:13 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Soligenix Inc.

      POS AM - SOLIGENIX, INC. (0000812796) (Filer)

      3/21/25 4:08:19 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Soligenix Inc.

      POS AM - SOLIGENIX, INC. (0000812796) (Filer)

      3/21/25 4:07:23 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Soligenix Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Parks Diane L.

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/13/24 5:37:47 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CSO Donini Oreola

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/13/24 4:26:41 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Guarino Jonathan L.

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/13/24 4:26:12 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SENIOR VICE PRESIDENT AND CMO Straube Richard

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/13/24 4:25:40 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHAIRMAN, CEO AND PRESIDENT Schaber Christopher J

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/13/24 4:24:22 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lapointe Anthony Gregg

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/13/24 4:23:34 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Zeldis Jerome B

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/13/24 4:22:49 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Rubin Robert J.

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/13/24 4:20:17 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Zeldis Jerome B

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/15/23 4:10:21 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Lapointe Anthony Gregg

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/15/23 4:10:12 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Soligenix Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders

      PRINCETON, N.J., Sept. 22, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 21, 2023 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on August 7, 2023 (the "Proxy Statement"). As a result of the additional ti

      9/22/23 4:00:00 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors

      Strengthens regulatory and orphan drug development expertise PRINCETON, N.J., May 3, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Timothy R. Coté, M.D., M.P.H. to its Board of Directors.  Dr. Coté is a leading national regulatory expert in orphan drug development. With 23 years of Federal service at the U.S. Food and Drug Administration (FDA), National Institu

      5/3/23 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting

              - Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time - Soligenix encourages all stockholders of record at the close of business on July 25, 2022 who have not yet voted, to vote by 11:59 p.m., Eastern Time on October 18, 2022 PRINCETON, N.J., Sept. 23, 2022 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2022 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 22, 2022 has been partially adjourned for the purpose of soliciting add

      9/23/22 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Appoints Industry Leader Diane Parks to its Board of Directors

      FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

      6/3/22 8:00:00 AM ET
      $CALT
      $CELU
      $CTIC
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Soligenix Inc. Financials

    Live finance-specific insights

    See more
    • Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (NASDAQ:NVA) and Soligenix Inc. (NASDAQ:SNGX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nova Minerals: https://www.redchip.com/assets/access/nva_accessSoligenix: https://www.redchip.com/assets/access/sngx_accessChristopher Gerteisen, CEO of Nova Minerals, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Nova Minerals p

      9/20/24 9:00:00 AM ET
      $BOXL
      $NVA
      $SNGX
      Other Consumer Services
      Real Estate
      Precious Metals
      Basic Materials
    • Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (NASDAQ:SNGX) and American Resources Corp. (NASDAQ:AREC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and CEO of Soligenix, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV

      8/16/24 9:00:00 AM ET
      $AREC
      $SNGX
      Coal Mining
      Energy
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B

      6/7/24 9:00:00 AM ET
      $SNGX
      $STSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / January 26, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Mobilicom Limited (NASDAQ:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessMobilicom: https://www.redchip.com/assets/access/mob_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and CEO of Soligenix, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a c

      1/26/24 9:00:00 AM ET
      $MOB
      $SNGX
      Aerospace
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 20, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and Soligenix, Inc. (NASDAQ:SNGX) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessSoligenix: https://www.redchip.com/assets/access/sngx_accessPaul Mann, CEO, of ASP Isotopes appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. ASP Isotopes successfully acquired t

      10/20/23 9:00:00 AM ET
      $ASPI
      $SNGX
      Major Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 13, 2023 / RedChip Companies will air interviews with SPI Energy Co., Ltd., (NASDAQ:SPI) and Soligenix, Inc. (NASDAQ:SNGX) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, October 14, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:SPI Energy: https://www.redchip.com/assets/access/spi_accessSoligenix: https://www.redchip.com/assets/access/sngx_accessDenton Peng, Chairman and CEO of SPI Energy, and Mark Hastings, Senior Vice President of Corporate Development and Strategy of Phoenix Motor, appear on the RedChip Sma

      10/13/23 9:00:00 AM ET
      $SNGX
      $SPI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Semiconductors
      Technology
    • Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (NASDAQ:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) on The RedChip Small Stocks Big Money Show®, a sponsored program on Bloomberg TV, this Saturday, October 7, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Knightscope: https://www.redchip.com/assets/access/knightscope_access.htmlSoligenix: https://www.redchip.com/assets/access/sngx_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessWilliam Santana Li, CEO and Chair

      10/6/23 9:00:00 AM ET
      $GENE
      $KSCP
      $SNGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Telecommunications Equipment
      Telecommunications
    • BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / August 11, 2023 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Soligenix, Inc. (NASDAQ:SNGX) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, August 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie (NASDAQ:BIVI): https://www.redchip.com/assets/access/bivi_accessSoligenix (NASDAQ:SNGX): https://www.redchip.com/assets/access/sngx_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' exper

      8/11/23 10:05:00 AM ET
      $BIVI
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

      ORLANDO, FL / ACCESSWIRE / June 2, 2023 / RedChip Companies will air new interviews with Soligenix, Inc. (NASDAQ:SNGX) and Graphex Group Limited (NYSE:GRFX) on The RedChip Money Report® on Bloomberg TV, this Saturday, June 3, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix, Inc.: https://www.sngxinfo.com/interview_accessGraphex Group Limited: https://www.grfxinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's

      6/2/23 9:00:00 AM ET
      $GRFX
      $SNGX
      Industrial Machinery/Components
      Energy
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results

      PRINCETON, N.J., March 31, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2022. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "2023 will be another important year for Soligenix. We are preparing for a Type A Meeting with the United States (U.S.) Food and Drug Administration (FDA) to discuss the contents of a refusal to file (RTF) letter issued by the FDA in response to the Co

      3/31/23 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care